Prevalence of FLEDR and TRAELDT in patients with SSc divided by clinical subtypes.

a<p>adjusted standardized residual >1.96 indicates that the number of cases in that cell is significantly larger than would be expected if the null hypothesis were true (represented in bold), with a significance level of.05. An adjusted residual < −2.0 indicates that the number of cases in that cell is significantly smaller than would be expected if the null hypothesis were true (represented in italic).</p>b<p>when comparing different subgroups for FLEDR association: DcSSc/LcSSc/healthy controls: χ² = 29.1, p<10⁻⁵; LcSSc/healthy controls: not significant; DcSSc/healthy controls: χ² = 28.4, p<10⁻⁶.</p>c<p>when comparing different subgroups for TRAELDT association: DcSSc/LcSSc/healthy controls: χ² = 10.2, p = 0.029; LcSSc/healthy controls: not significant; DcSSc/healthy controls: χ² = 7.2, p = 0.027.</p

Prevalence of FLEDR and TRAELDT in patients with SSc divided by antibody status.

a<p>adjusted standardized residual >1.96 indicates that the number of cases in that cell is significantly larger than would be expected if the null hypothesis were true (represented in bold), with a significance level of.05. An adjusted residual < −2.0 indicates that the number of cases in that cell is significantly smaller than would be expected if the null hypothesis were true (represented in italic).</p>b<p>when comparing different subgroups for FLEDR association: Ab neg/ACA pos/ATA pos/healthy controls: χ² = 48.5, p<10⁻⁸; Ab neg/healthy controls: not significant; ACA pos/healthy controls: χ² = 0.17, p = 0.9; ATA pos: χ² = 43.9, p<10⁻⁹.</p>c<p>when comparing different subgroups for TRAELDT association: Ab neg/ACA pos/ATA pos/healthy controls: χ² = 27.6, p = 0.00013; Ab neg/healthy controls: not significant; ACA pos: χ² = 7.9, p = 0.02; ATA pos/healthy controls: χ² = 14.6, p = 0.0007.</p

Shared amino acid sequences of the most common DRß chains.

<p>Shared amino acid sequences of the most common DRß chains.</p

mRNA expression of DRB5*01 and DRB1*15 in patients with SSc and controls (CTL).

<p>mRNA expression of DRB5*01 and DRB1*15 in patients with SSc and controls (CTL).</p

Autoantibodies against A) EphB2 and B) THEX1 analyzed in subgroups of patients with lupus.

<p>Sera reactivity against EphB2 or THEX1 is given by Absorbance (Abs) value for patients with Systemic Lupus Erythematosus (SLE), positive for anti-dsDNA antibodies (dsDNA^pos) or negative (dsDNA^neg) and compared to all controls (CTLS) including healthy controls (HC) and controls with other Rheumatic diseases (RD), with a total of n = 166 with 85 HC and 81 RD for EphB2 and n = 180 with 99 HC and 81 RD for THEX1. Sera were tested at dilution 1/100 and defined as positive when Abs≥0 (on or above the dotted blue line). Red bars represent medians with interquartile ranges. Percentage of individuals positive for anti-EphB2 or THEX1 antibodies are indicated in the upper part of the graph. All P values are calculated using Mann Whitney test by comparing Abs results from patients with SLE as a whole group or in SLE subgroups to all controls (CTLS).</p

Clinical and serological characteristics of patients with SSc either positive or negative for anti-EphB2 or -THEX1 antibodies.

<p>Clinical and serological characteristics of patients with SSc either positive or negative for anti-EphB2 or -THEX1 antibodies.</p

Autoantibodies against A) EphB2 and B) THEX1 analyzed in patients with scleroderma.

<p>Sera reactivity against A) EphB2 or B) THEX1 is given by Absorbance (Abs) value for patients with systemic sclerosis (SSc), patients with SSc positive for anti-topoisomerase antibody (ATA^pos), positive for anti-centromere antibody (ACA^pos) or negative for both (ACA/ATA^neg), and compared to all controls (CTLS) including healthy controls (HC) and controls with other Rheumatic diseases (RD), with a total of n = 166 with 85 HC and 81 RD for EphB2 and n = 180 with 99 HC and 81 RD for THEX1. Sera were tested at dilution 1/100 and defined as positive when Abs≥0 (on or above the dotted blue line). Red bars represent medians with interquartile ranges. Percentage of individuals positive for anti-EphB2 or THEX1 antibodies are indicated in the upper part of the graph. All P values are calculated using Mann Whitney test by comparing Abs results from patients with SSc as a whole group or in SSc subgroups to all controls (CTLS).</p

Autoantibodies against peptide 7 (P7 from EphB2 protein) analyzed in patients with scleroderma (SSc), lupus (SLE), Rheumatoid Arthritis (RA) and healthy controls (HC).

<p>Sera reactivity against the peptide 7 (P7 at 10μg/well) is given by Absorbance (Abs) values for all patients and controls. Sera were tested at dilution 1/100 and defined as positive when Abs≥0 (on or above the dotted blue line). Red bars represent medians with interquartile ranges. Percentage of individuals positive for anti-P7 antibodies are indicated in the upper part of the graph. One data point for SLE is outside the Y axis limit (-0,41) and not represented here but counted for statistics. P value is calculated using Mann Whitney test by comparing patients with SLE to all controls (SSc, RA and HC, n = 157).</p

Protoarray results of candidate proteins.

<p>Protoarray results of candidate proteins.</p

Clinical and serological characteristics of patients with SLE, positive or negative for anti-EphB2 or -THEX1 antibodies.

<p>Clinical and serological characteristics of patients with SLE, positive or negative for anti-EphB2 or -THEX1 antibodies.</p